CaroGen
CaroGen is a pre-clinical, privately-held biotechnology company developing RNA-based immunotherapy and vaccine candidates — including CARG-201 for chronic Hepatitis B and CARG-2020 for ovarian cancer — built on its AVIDIO Platform licensed from Yale University School of Medicine.
- Company typePrivate
- Founded2012
- HeadquartersHamden, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CaroGen does
CaroGen Corporation is a privately-held, pre-clinical biotechnology company headquartered in Farmington, Connecticut that develops immunotherapies and vaccine candidates based on its proprietary AVIDIO Platform — an RNA-based artificial virus platform composed of components from two non-human-infectious viruses (SFV and VSV), exclusively licensed worldwide from Yale University School of Medicine. The platform supports delivery of multiple transgenes and generation of broad immune responses, and is applied to two lead candidates in late-stage IND-enabling studies: CARG-201, a chronic Hepatitis B candidate designed to enable functional cure by reducing HBV surface antigens, and CARG-2020, an ovarian cancer immunotherapy combining IL-12, an IL-17R antagonist, and shRNA-PD-L1 to amplify, expand, and sustain anti-tumor immunity and prevent tumor recurrence. The company also collaborates with NIAID/NIH on a universal influenza vaccine and with UConn Health on colorectal cancer, indicating platform optionality beyond the lead assets.
CaroGen is pre-commercial and pre-revenue. Its business model is presently grant-driven: the HBV program alone has been supported by more than $16 million in NIH and U.S. Department of Defense grants, with an additional $6.8 million DoD award recommended in late 2023. The company expects continued federal support through Phase 1 clinical studies, and its stated forward commercialization path relies on pharmaceutical licensing partnerships and royalties rather than direct sales. Customer-facing activity is concentrated in scientific publications, conferences, and academic collaborations, consistent with a pre-commercial biotech whose end markets — chronic HBV (over 250 million patients globally) and ovarian cancer — are large but require multi-year regulatory advancement before revenue realization.
CaroGen firmographics
Firmographics- Name
- CaroGen
- Legal name
- CaroGen Corporation
- Website
- https://carogencorp.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CaroGen is a pre-clinical, privately-held biotechnology company developing RNA-based immunotherapy and vaccine candidates — including CARG-201 for chronic Hepatitis B and CARG-2020 for ovarian cancer — built on its AVIDIO Platform licensed from Yale University School of Medicine.
- Ownership category
- akta.pro rank
CaroGen industry classification
Industry- Product category
- Biopharmaceutical Immunotherapies
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where CaroGen is headquartered
LocationHeadquarters
- HQ city
- Hamden
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CaroGen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Grant Funding: HBV program supported by over $16 million in NIH & DoD grants. Company has received recommended funding of $6.8M from Department of Defense for HBV immunotherapy advancement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CaroGen product offering
Product offeringCore offering
CaroGen Corporation is a clinical-stage biotechnology company developing transformative immunotherapies based on its proprietary AVIDIO Platform, an RNA-based artificial virus technology. Its two lead candidates in late-stage pre-clinical (IND-enabling) development are CARG-201 for chronic Hepatitis B functional cure and CARG-2020 for ovarian cancer and solid tumor immunotherapy. The platform is exclusively licensed from Yale University and designed to deliver multiple transgenes while avoiding pre-existing human immunity.
Product overview
CaroGen Corporation is an immunotherapy company developing a portfolio of products based on its proprietary virus-like vesicle (VLV) platform technology pioneered at Yale University. The AVIDIO Platform serves as the core technology enabling RNA-based artificial virus delivery for immunotherapy development. The company has two clinical candidates in late-stage pre-clinical (IND-enabling) studies: CARG-201 for chronic Hepatitis B and CARG-2020 for oncology (ovarian cancer). The VLV platform is exclusively licensed to CaroGen for worldwide development and commercialization of immunotherapies against infectious diseases and cancer.
Differentiator
Problem solved
Functional benefit
Brands
- AVIDIO Platform: Artificial Virus for Infectious Disease & Immuno-Oncology - RNA-based artificial virus platform composed of components of SFV and VSV viruses, with capacity to deliver multiple transgenes and generate broad immune responses.
- CARG-201
- CARG-2020
Products and services
- AVIDIO Platform Proprietary RNA-based artificial virus platform composed of components from SFV and VSV viruses, enabling delivery of multiple transgenes and generation of broad-spectrum immune responses for developing immunotherapies against infectious diseases and cancer. It is the foundational technology licensed exclusively from Yale University School of Medicine.
- CARG-201 Pre-clinical immunotherapy candidate targeting functional cure of chronic Hepatitis B virus infection. It enables robust expression and secretion of Hepatitis B middle S and core antigens, with demonstrated reduction of HBV surface antigens by more than 2 logs in AAV model studies.
- CARG-2020 Immuno-oncology candidate targeting ovarian cancer and solid tumors to prevent tumor recurrence, using a triple mechanism: IL-12 to amplify anti-cancer immune response by inducing T cells, IL-17R antagonist to block tumor-promoting IL-17RA, and shRNA-PD-L1 to prevent T cell exhaustion.
Companies that use CaroGen
Customer profileSegments3 records
Ideal customer profiles3 records
CaroGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CaroGen partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NIAID/NIH (National Institute of Allergy and Infectious Diseases)coreCaroGen partnered with NIAID/NIH scientists to develop a universal influenza vaccine. This collaboration leverages the AVIDIO platform technology for infectious disease applications.
- Wayne State UniversitycoreCollaboration with scientists at C.S. Mott Center for Human Growth and Development at Wayne State University for development of CARG-2020 for ovarian cancer treatment. Research team includes Dr. Ayesha Alvero, MD, MSc.
- UConn HealthminorCollaboration with UConn Health researchers on promising technology for colorectal cancer treatment using the VLV platform.
- Yale University School of MedicinecoreVLV platform technology pioneered by Professor John Rose at Yale University School of Medicine is exclusively licensed by CaroGen for worldwide development and commercialization.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
CaroGen competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
CaroGen social profiles
Digital presenceCaroGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
CaroGen leadership team
Management profileNumber of profiles
Profiles9 records
CaroGen funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CaroGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CaroGen
What does CaroGen do?
CaroGen Corporation is a clinical-stage biotechnology company developing transformative immunotherapies based on its proprietary AVIDIO Platform, an RNA-based artificial virus technology. Its two lead candidates in late-stage pre-clinical (IND-enabling) development are CARG-201 for chronic Hepatitis B functional cure and CARG-2020 for ovarian cancer and solid tumor immunotherapy. The platform is exclusively licensed from Yale University and designed to deliver multiple transgenes while avoiding pre-existing human immunity.
Is CaroGen a public or private company?
CaroGen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CaroGen founded?
CaroGen was founded in 2012. It employs 1 to 10 people.
Where is CaroGen based?
CaroGen is headquartered in Hamden, United States, in the North America region.
How does CaroGen make money?
One revenue line is on record: grant Funding.
Does CaroGen have an API?
No public API is recorded for CaroGen.
What industry is CaroGen in?
CaroGen's product category is Biopharmaceutical Immunotherapies. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2836.